RP-HPLC Method for Development, Validation and Assay of Desidustat in Pharmaceutical Formulation

  • Unique Paper ID: 167480
  • Volume: 11
  • Issue: 3
  • PageNo: 1685-1698
  • Abstract:
  • Desidustat is an orally bioavailable, hypoxia- inducible factor prolyl hydroxylase inhibitor and used to treat anemia of chronic kidney disease. An accurate, precise and robust reverse phase HPLC methods was developed and validated as per ICH guideline. An analytical column eclipse XDB C18 (150x4.6 mm,5µ) was used at flow rate 1.0 ml/min in the mobile phase ratio of 0.1% orthophosphoric acid and methanol 38:72 at 235 nm wavelength. These approach can be effectively utilized for the development and validation of desidustat in pharmaceutical formulation.

Cite This Article

  • ISSN: 2349-6002
  • Volume: 11
  • Issue: 3
  • PageNo: 1685-1698

RP-HPLC Method for Development, Validation and Assay of Desidustat in Pharmaceutical Formulation

Related Articles